Sources checked October 21, 2026. FDA documents below were recovered from dated archives, identified beside each policy summary. This page describes preparation, documentation and study findings; it does not recommend a product, dose or treatment.
Is compounded tirzepatide the same as a generic drug?
No. FDA distinguishes an approved generic from a compounded preparation: the generic has an FDA approval under section 505(j), while the compounded drug does not. This distinction comes from FDA's September 16, 2025 Q&A, archived October 15, 2026.[1]
Compounding can occur in state-licensed pharmacies, federal facilities, physicians' practices or registered outsourcing facilities. The website taking an order and the facility preparing the medicine should be identified separately when requesting documentation.[1]
What changed after the tirzepatide shortage ended?
FDA's policy page, archived October 15, 2026, records a December 19, 2024 decision that the tirzepatide injection shortage was resolved.[2]
Its March 10, 2025 update says shortage-related enforcement discretion had ended for section 503A compounders after the March 5 court decision. For section 503B outsourcing facilities, it gave March 19, 2025 as the endpoint.[2]
The April 1, 2026 clarification describes section 503A patient-specific prescriptions and restrictions on regularly making essentially copies. It identifies a prescriber's documented significant difference for an identified patient as relevant to that copy determination.[2]
For section 503B bulk ingredients, the same update identifies the bulks list or shortage-list route and says tirzepatide was on neither list. These dated statements do not establish a particular pharmacy's present legal position.[2]
Did FDA propose another change in 2026?
On April 30, 2026, FDA announced a proposal to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list. The notice gave June 29, 2026 as the comment deadline and said comments would be considered before a final determination.[3]
The recovered September 24, 2026 archive still describes a proposal. This source does not establish whether a later final determination occurred. A proposal, the existing list and an individual prescription are separate questions.[3]
What have compounded tirzepatide studies measured?
The following reports examine different questions. A single-person observation, a matched retrospective comparison and a documentation study are not interchangeable evidence.
What did the 2025 single-person report observe?
Guth's January-February 2025 journal report describes one male investigator aged 55 to 65 without type 2 diabetes who received compounded tirzepatide injections for four weeks. Its original abstract reports 5% body-weight reduction during treatment and 5% regain within two weeks after the study ended.[4]
This was the investigator's self-experiment, not a randomized comparison. It supplies one person's observations, not a population estimate or a dosing recommendation. Only the original abstract was available for this review.[4]
What did the 2026 matched-cohort preprint report?
Erly and Raja's July 16, 2026 medRxiv preprint analyzed Mochi Health records. Among people with a six-month weight observation, 869 used branded tirzepatide and 6,402 used compounded tirzepatide; switchers were excluded. Matching produced 718 branded-compounded pairs.[5]
The authors reported mean six-month weight losses of 11.44% and 11.37%, respectively, with a reported difference of 0.08 percentage points and a 95% confidence interval from -0.70 to 0.80. Their prespecified equivalence test used a two-percentage-point margin. This was retrospective, not randomized; the preprint is not a peer-reviewed trial.[5]
What does that comparison leave unestablished?
The preprint distinguishes its statistical comparison from pharmacologic bioequivalence. It lacks a pharmacy-specific analysis, does not establish adverse-event rates and leaves metformin and socioeconomic confounding unresolved. Both authors disclose contractor relationships with Mochi Health. Recorded six-month weights select a subset of the program's patients.[5]
What did primary-care records document?
Hendrix and colleagues examined 153,044 patients with semaglutide or tirzepatide records from January 2021 through December 2024. Their 2025 scientific abstract reports 8.2% with compounded-formulation use; its plain-language summary says 8.3%. The discrepancy is unresolved here.[6]
This study combines both drugs and measures documentation, not tirzepatide-specific treatment outcomes. It identified branded prescriptions through structured records and compounded use through clinical notes. Its denominator is not the number of US patients obtaining compounded tirzepatide.[6]
What should you ask the prescriber and pharmacy?
Ask for the prescriber's name, the dispensing pharmacy's legal name and the name of the facility that prepared the medicine. Ask which state regulator or FDA registration record corresponds to that facility. FDA's Q&A distinguishes state-pharmacy oversight from oversight of registered outsourcing facilities.[1]
Request a written description of the preparation, its ingredients, its labeled concentration and the pharmacy's instructions. Ask the prescriber to explain the patient-specific reason for the proposed preparation and which regulatory pathway the pharmacy is using. These are documentation questions, not directions to select a formulation or convert a dose.
For a quote, separate the medication charge from consultation, laboratory, shipping and recurring service charges. Request the billing period and cancellation terms in writing. This page does not quote a current price or commit any provider to supplying a prescription.
Where can you browse related clinic listings?
Regenerated.com's September 2026 export contains 2,743 records tagged Peptide Therapy among 9,042 published clinic records, across 49 states plus Washington, DC. Source: the September clinic export and its Peptide Therapy directory-facts file. This is historical directory coverage, not market size or a count of compounded tirzepatide prescribers.
Browse the national Peptide Therapy clinic directory to compare listed practices. Geographic starting points include Peptide Therapy clinics in Gilbert, Arizona and Peptide Therapy clinics in Aurora, Colorado. These categories do not confirm that a practice prescribes, prepares or dispenses compounded tirzepatide. Ask each practice directly.